Lee Jee Young, Roh Ju-Won, Han Kyung-Hee, Kim Min-Jeong, Na Young Jeong, Yun Bo Seong, Lee Joohyun
Department of Korean Medicine, Integrative Cancer Center, CHA Ilsan Medical Center, CHA University, Goyang-si, Republic of Korea.
Department of Obstetrics and Gynecology, CHA Ilsan Medical Center, CHA University, Goyang-si, Republic of Korea.
JMIR Res Protoc. 2025 Jul 22;14:e77009. doi: 10.2196/77009.
Reducing blood pressure fluctuations during surgery is a key objective in improving patient outcomes. Although acupuncture has been suggested as a potential noninvasive intervention for blood pressure modulation, its effectiveness in reducing intraoperative fluctuations remains unclear.
This study aims to investigate whether acupuncture can help stabilize blood pressure during surgery, particularly in women undergoing laparoscopic hysterectomy, a procedure known to cause marked hemodynamic changes during the early intraoperative phase.
This is a prospective, single-center, randomized controlled clinical trial with a parallel-group design. Forty-eight adult patients scheduled to undergo a total laparoscopic hysterectomy are eligible for this study. Participants who provide consent will be randomly assigned in a 1:1 ratio to the acupuncture or placebo groups. They will be followed up for at least 14 days to assess the safety of the intervention, general anesthesia, and surgery. Researchers will compare the difference between the highest and lowest mean blood pressures from anesthesia induction to the postincision period as the primary endpoint. As secondary outcomes, systolic, diastolic, and mean blood pressures will be compared at each predetermined timepoint. The incidences of hypotension, hypertension, tachycardia, and bradycardia will be determined separately. The use of remifentanil at the early stage of surgery, rate of surgical discontinuation, and length of hospital stay will be assessed as surrogate indicators of stable general anesthesia and surgical procedures. For patient-reported outcomes, the Spielberger State-Trait Anxiety Inventory and EQ-5D-5L will be used to evaluate changes in anxiety and overall quality of life. This study may support the use of acupuncture as a complementary intervention to help maintain hemodynamic stability during laparoscopic hysterectomy. The study will be conducted in accordance with the Declaration of Helsinki and has been approved by the Institutional Review Board of CHA Ilsan Medical Center (ICHA 2022-11-010; date of approval: January 03, 2023).
Recruitment began in October 2023 and is expected to continue until December 2025. The intervention and data collection procedures are proceeding without major difficulties, with a dropout rate of 11.4%. As of June 2025, a total of 35 participants have been successfully recruited and randomized. Final data analysis is scheduled for completion by March 2026, and the study results are expected to be published in December 2026.
This trial will provide valuable evidence on the efficacy of acupuncture for stabilizing intraoperative blood pressure and supporting hemodynamic control during laparoscopic hysterectomy.
ClinicalTrials.gov NCT05720884; https://clinicaltrials.gov/study/NCT05720884.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/77009.
减少手术期间的血压波动是改善患者预后的关键目标。尽管针灸已被认为是一种潜在的无创血压调节干预手段,但其在减少术中波动方面的有效性仍不明确。
本研究旨在探讨针灸是否有助于在手术期间稳定血压,特别是在接受腹腔镜子宫切除术的女性中,该手术在术中早期会引起明显的血流动力学变化。
这是一项前瞻性、单中心、随机对照临床试验,采用平行组设计。计划接受全腹腔镜子宫切除术的48名成年患者符合本研究条件。提供同意的参与者将按1:1的比例随机分配到针灸组或安慰剂组。他们将接受至少14天的随访,以评估干预措施、全身麻醉和手术的安全性。研究人员将比较从麻醉诱导到切口后阶段最高和最低平均血压之间的差异作为主要终点。作为次要结果,将在每个预定时间点比较收缩压、舒张压和平均血压。将分别确定低血压、高血压、心动过速和心动过缓的发生率。手术早期瑞芬太尼的使用、手术中断率和住院时间将作为全身麻醉和手术过程稳定的替代指标进行评估。对于患者报告的结果,将使用斯皮尔伯格状态-特质焦虑量表和EQ-5D-5L来评估焦虑和总体生活质量的变化。本研究可能支持使用针灸作为一种辅助干预措施,以帮助在腹腔镜子宫切除术中维持血流动力学稳定。本研究将按照《赫尔辛基宣言》进行,并已获得CHA Ilsan医疗中心机构审查委员会的批准(ICHA 2022-11-010;批准日期:2023年1月3日)。
招募工作于2023年10月开始,预计将持续到2025年 December。干预和数据收集程序进展顺利,无重大困难,脱落率为11.4%。截至2025年6月,共成功招募并随机分配了35名参与者。最终数据分析计划于2026年3月完成,研究结果预计于2026年12月发表。
本试验将为针灸在腹腔镜子宫切除术中稳定术中血压和支持血流动力学控制的疗效提供有价值的证据。
ClinicalTrials.gov NCT05720884;https://clinicaltrials.gov/study/NCT05720884。
国际注册报告识别码(IRRID):DERR1-10.2196/77009。